Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma

被引:3
|
作者
Fernandez-miranda, Ismael [1 ]
Pedrosa, Lucia [1 ]
Gonzalez-Rincon, Julia [1 ,2 ]
Espinet, Blanca [3 ,4 ]
Vicente, Fatima de la Cruz [5 ]
Climent, Fina [6 ]
Gomez, Sagrario [1 ]
Royuela, Ana [7 ]
Camacho, Francisca I. [8 ]
Martin-Acosta, Paloma [9 ]
Yanguas-Casas, Natalia [1 ,10 ]
Dominguez, Marina [1 ]
Mendez, Miriam [1 ,11 ]
Colomo, Luis [3 ]
Salar, Antonio [11 ,12 ]
Horcajo, Beatriz [1 ]
Navarro, Marta [1 ]
Garcia-Cosio, Monica [12 ,13 ]
Piris-Villaespesa, Miguel [13 ,14 ]
Llanos, Marta [14 ,15 ]
Garcia, Juan F. [16 ]
Sequero, Silvia [16 ,17 ]
Mercadal, Santiago [17 ,18 ]
Garcia-Hernandez, Sonia [19 ]
Navarro, Belen [20 ]
Mollejo, Manuela [21 ]
Provencio, Mariano [1 ,22 ]
Sanchez-Beato, Margarita [1 ]
机构
[1] Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, Lymphoma Res Grp, IDIPHISA, Majadahonda, Madrid, Spain
[2] Fujitsu Technol Solut SA, CoE Data Intelligence, Camino Cerro Gamos 1,Pozuelo Alarcon, Madrid, Spain
[3] Inst Hosp Mar Investigac Med IMIM, Canc Res Program, Translat Res Hematol Neoplasms Grp, Barcelona, Spain
[4] Hosp del Mar, Dept Pathol, Barcelona, Spain
[5] Univ Seville, Univ Hosp Virgen Rocio, Dept Hematol, Inst Biomed Sevilla IBIS CSIC CIBERONC, Seville, Spain
[6] Hosp Univ Bellvitge, Dept Pathol, IDIBELL, Barcelona, Spain
[7] Hosp Univ Puerta Hierro Majadahonda, Biostat Unit, IDIPHISA, CIBERESP, Madrid, Spain
[8] Hosp Univ Getafe, Dept Pathol, Madrid, Spain
[9] Hosp Univ Puerta Hierro Majadahonda, Dept Pathol, Canc Mol Pathol Grp, IDIPHISA, Majadahonda, Madrid, Spain
[10] Ctr Invest Biomed Red Fragil & Envejecimiento Salu, Madrid, Spain
[11] Hosp Univ Puerta HierroMajadahonda, Dept Med Oncol, IDIPHISA, Madrid, Spain
[12] Hosp del Mar, Dept Hematol, Barcelona, Spain
[13] Hosp Univ Ramon y Cajal, Dept Pathol, Madrid, Spain
[14] Hosp Univ Ramon y Cajal, Dept Hematol, Madrid, Spain
[15] Hosp Univ Canarias, Dept Oncol, Tenerife, Spain
[16] Hosp MD Anderson Canc Ctr, Dept Pathol, Madrid, Spain
[17] Hosp Univ San Cecilio, Dept Oncol, Granada, Spain
[18] Hosp Duran i Reynals, Dept Hematol, ICO, Barcelona, Spain
[19] Hosp Univ Canarias, Dept Pathol, Tenerife, Spain
[20] Hosp Univ Puerta Hierro, Dept Hematol, Majadahonda, Madrid, Spain
[21] Complejo Hosp Toledo, Dept Pathol, Toledo, Spain
[22] Univ Autonoma Madrid, Hosp Univ Puerta Hierro Majadahonda, Fac Med, Dept Med Oncol, Majadahonda, Madrid, Spain
关键词
follicular lymphoma; genomics; histologic transformation; predictive model; PROGNOSTIC INDEX FLIPI; 1ST-LINE IMMUNOCHEMOTHERAPY; TNFRSF14; MUTATIONS; EARLY PROGRESSION; SURVIVAL; GENETICS; OUTCOMES; RITUXIMAB; ERA;
D O I
10.1016/j.modpat.2024.100516
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Follicular lymphoma (FL) is the most frequent indolent lymphoma. Some patients (10%-15%) experience histologic transformation (HT) to a more aggressive lymphoma, usually diffuse large Bcell lymphoma (DLBCL). This study aimed to validate and improve a genetic risk model to predict HT at diagnosis.We collected mutational data from diagnosis biopsies of 64 FL patients. We combined them with the data from a previously published cohort (total n 1/4 104; 62 from nontransformed and 42 from patients who did transform to DLBCL). This combined cohort was used to develop a nomogram to estimate the risk of HT. Prognostic mutated genes and clinical variables were assessed using Cox regression analysis to generate a risk model. The model was internally validated by bootstrapping and externally validated in an independent cohort. Its performance was evaluated using a concordance index and a calibration curve. The clinicogenetic nomogram included the mutational status of 3 genes (HIST1HE1, KMT2D, and TNFSR14) and high-risk Follicular Lymphoma International Prognostic Index and predicted HT with a concordance index of 0.746. Patients were classified as being at low or high risk of transformation. The probability HT function at 24 months was 0.90 in the low-risk group vs 0.51 in the high-risk group and, at 60 months, 0.71 vs 0.15, respectively. In the external validation cohort, the probability HT function in the low-risk group was 0.86 vs 0.54 in the high-risk group at 24 months, and 0.71 vs 0.32 at 60 months. The concordance index in the external cohort was 0.552. In conclusion, we propose a clinicogenetic risk model to predict FL HT to DLBLC, combining genetic alterations in HIST1H1E, KMT2D, and TNFRSF14 genes and clinical features (Follicular Lymphoma International Prognostic Index) at diagnosis. This model could improve the management of FL patients and allow treatment strategies that would prevent or delay transformation. (c) 2024 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients
    Bastion, Y
    Sebban, C
    Berger, F
    Felman, P
    Salles, G
    Dumontet, C
    Bryon, PA
    Coiffier, B
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) : 1587 - 1594
  • [22] Glycolytic biomarkers predict transformation in patients with follicular lymphoma
    Monrad, Ida
    Madsen, Charlotte
    Lauridsen, Kristina Lystlund
    Honore, Bent
    Plesner, Trine Lindhardt
    Hamilton-Dutoit, Stephen
    d'Amore, Francesco
    Ludvigsen, Maja
    PLOS ONE, 2020, 15 (05):
  • [23] Glycolytic Biomarkers Predictive of Transformation in Patients with Follicular Lymphoma
    Monrad, Ida
    Madsen, Charlotte
    Lauridsen, Kristina
    Honore, Bent
    Plesner, Trine Lindhardt
    Hamilton-Dutoit, Stephen
    d'Amore, Francesco
    Ludvigsen, Maja
    BLOOD, 2019, 134
  • [24] Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
    Federico, Massimo
    Caballero Barrigon, Maria Dolores
    Marcheselli, Luigi
    Tarantino, Vittoria
    Manni, Martina
    Sarkozy, Clementine
    Alonso-Alvarez, Sara
    Wondergem, Marielle
    Cartron, Guillaume
    Lopez-Guillermo, Armando
    Issa, Djamila
    Morschhauser, Franck
    Alcoceba, Miguel
    Kimby, Eva
    Rusconi, Chiara
    Chamuleau, Martine
    Holte, Harald
    Lockmer, Sandra
    Montoto, Silvia
    da Silva, Maria Gomes
    Aurer, Igor
    Zucca, Emanuele
    Paszkiewicz-Kozik, Ewa
    Minoia, Carla
    Skrypets, Tetiana
    Blaker, Yngvild Nuvin
    Salles, Gilles
    Coiffier, Bertrand
    LANCET HAEMATOLOGY, 2018, 5 (08): : E359 - E367
  • [25] Incidence, risk factors and outcome of histological transformation in follicular lymphoma
    Conconi, Annarita
    Ponzio, Carlotta
    Lobetti-Bodoni, Chiara
    Motta, Maddalena
    Rancoita, Paola M. V.
    Stathis, Anastasios
    Moccia, Alden A.
    Mazzucchelli, Luca
    Bertoni, Francesco
    Ghielmini, Michele
    Cavalli, Franco
    Zucca, Emanuele
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (02) : 188 - 196
  • [26] External Validation of the Model of Thromboembolic Risk in Hypertrophic Cardiomyopathy Patients
    He, Sen
    Wang, Ziqiong
    Cheem, Tan Huay
    Liao, Hang
    Chen, Xiaoping
    He, Yong
    CANADIAN JOURNAL OF CARDIOLOGY, 2019, 35 (12) : 1800 - 1806
  • [27] Vascularization predicts overall survival and risk of transformation in follicular lymphoma
    Farinha, Pedro
    Kyle, Alastair H.
    Minchinton, Andrew I.
    Connors, Joseph M.
    Karsan, Aly
    Gascoyne, Randy D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (12): : 2157 - 2160
  • [28] Histologic Transformation from Follicular Lymphoma to Diffuse Large B-cell Lymphoma Detected during Colonoscopy
    Iwamuro, Masaya
    Yamasaki, Yasushi
    Tanaka, Takehiro
    Asada, Noboru
    Matsuoka, Ken-Ichi
    Hiraoka, Sakiko
    Kawahara, Yoshiro
    Okada, Hiroyuki
    ACTA MEDICA OKAYAMA, 2021, 75 (05) : 625 - 629
  • [29] HISTOLOGIC TRANSFORMATION OF FOLLICULAR LYMPHOMA TO DIFFUSE LYMPHOMA REPRESENTS TUMOR PROGRESSION BY A SINGLE MALIGNANT B-CELL
    ZELENETZ, AD
    CHEN, TT
    LEVY, R
    JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (01): : 197 - 207
  • [30] RISK OF HISTOLOGIC TRANSFORMATION (HT) IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) PATIENTS TREATED WITH RITUXIMAB
    Kalpadakis, C.
    Pangalis, G.
    Sachanas, S.
    Vassilakopoulos, T.
    Rondogianni, D.
    Dimitrakopoulou, A.
    Koulieris, E.
    Moschogiannis, M.
    Yiakoumis, X.
    Psyllaki, M.
    Tsirkinidis, P.
    Papadaki, H.
    Panayiotidis, P.
    Angelopoulou, M.
    HAEMATOLOGICA, 2016, 101 : 754 - 754